Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient Investors

Resumen detallado
The dividend is hefty -- and it's been growing briskly, too.
There are exciting headlines galore regarding Danish healthcare company Novo Nordisk (NVO -1.42%):
See? It's enough to make one itch to become a shareholder. The stock is well worth considering for your portfolio. But look beyond the headlines, and you'll see another compelling reason to invest in Novo Nordisk: its dividend. The payout recently yielded a fat 4.6% (and when you add in the effect of share repurchases, the total shareholder yield comes in at about 5.5%). For comparison, the S&P 500 index of America's 500 largest companies recently yielded a mere 1%.
It's a growing dividend, too. Unlike American dividend-paying companies, which generally pay dividends quarterly, Novo Nordisk pays twice a year, offering an "annual" dividend and an "interim" one. Together, they totaled $1.85 per share in 2026, and that's up from $0.81 in 2022 and $0.62 in 2019.
Better still, the company's payout ratio -- the percentage of earnings being paid out in dividends -- was recently just 45%. That number suggests that Novo Nordisk shouldn't have any trouble paying future dividends, and that there's plenty of room for further growth.
So -- should you invest in Novo Nordisk? Certainly consider it, especially if you're seeking both income and growth. The shares seem reasonably or appealingly valued at recent levels, with a recent price-to-sales ratio of 3.5, well below the five-year average of 8.1, and a recent forward-looking price-to-earnings (P/E) ratio of 12.3, not far from the five-year average of 11.9.
Beyond the stock's valuation, Novo Nordisk's business is attractive. It has long been a force in treating diabetes, but now it's also operating in the weight-loss drug realm, with success. Perhaps most promising is its oral GLP-1 drug, which is preferable to a regular injection for many -- and which will soon be available in 20-plus markets.
The company does face competition, and it has had some setbacks in clinical trials, but its pipeline remains promising.
When our analyst team has…
T…
Inicio del artículo, extracto de The Motley Fool. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)




